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Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) is an important neurotrophic factor influencing differentiation of
neuronal elements and exerting protecting role during traumatic injuries or inflammatory processes of the central nervous
system. Although increasing evidence is available on its presence and protecting function in various peripheral tissues, little
is known about the role of PACAP in formation of skeletal components. To this end, we aimed to map elements of PACAP
signalling in developing cartilage under physiological conditions and during oxidative stress. mRNAs of PACAP and its
receptors (PAC1,VPAC1, VPAC2) were detectable during differentiation of chicken limb bud-derived chondrogenic cells in
micromass cell cultures. Expression of PAC1 protein showed a peak on days of final commitment of chondrogenic cells.
Administration of either the PAC1 receptor agonist PACAP 1-38, or PACAP 6-38 that is generally used as a PAC1 antagonist,
augmented cartilage formation, stimulated cell proliferation and enhanced PAC1 and Sox9 protein expression. Both variants
of PACAP elevated the protein expression and activity of the Ca-calmodulin dependent Ser/Thr protein phosphatase
calcineurin. Application of PACAPs failed to rescue cartilage formation when the activity of calcineurin was
pharmacologically inhibited with cyclosporine A. Moreover, exogenous PACAPs prevented diminishing of cartilage
formation and decrease of calcineurin activity during oxidative stress. As an unexpected phenomenon, PACAP 6-38 elicited
similar effects to those of PACAP 1-38, although to a different extent. On the basis of the above results, we propose
calcineurin as a downstream target of PACAP signalling in differentiating chondrocytes either in normal or
pathophysiological conditions. Our observations imply the therapeutical perspective that PACAP can be applied as a
natural agent that may have protecting effect during joint inflammation and/or may promote cartilage regeneration during
degenerative diseases of articular cartilage.
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Introduction
Originally isolated from ovine hypothalamic extracts, pituitary
adenylate cyclase activating polypeptide (PACAP) is a member of
the VIP–Secretin–GHRH–Glucagon superfamily [1]. The active
neuropeptide comprises 38 amino acid residues (PACAP 1-38);
however, a shorter a-amidated form that corresponds to the first
27 residues at the N-terminus (PACAP 1-27) also exists, suggesting
that their biologically active region is completely preserved during
evolution [1]. PACAP 1-38, the dominant form of the neuropep-
tide, is widely distributed in the central nervous system (CNS) and
is also present in several peripheral tissues such as gonads [2],
intestinal system [3], urinary tract [4], as well as in fluid
compartments including blood plasma [5] and human milk [6].
In spite of the large variety of tissues containing or releasing
PACAP, there are only sporadic data about its function in skeletal
elements such as bone [7–9]; in particular, its presence in hyaline
cartilage has not been reported. PACAP is a multifunctional
peptide that can regulate diverse physiological processes such as
testicular ageing [10], circadian rhythm [11], brain development
[12] or cell migration [13]. PACAP is also regarded as a
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neurotrophic [14,15] and anti-inflammatory substance in the CNS
[16] and is reported to prevent harmful effects of oxidative stress in
various tissues [17–19].
So far, three G protein-coupled receptors have been identified
on which PACAP can act: PAC1, VPAC1 and VPAC2 [20].
PACAP and VIP bind to VPAC1 and VPAC2 with similar
affinity, while PAC1 receptor has approximately 100-fold greater
affinity to PACAP [21]. PACAP 6-38, a peptide that lacks the first
5 amino acids from the N-terminus of PACAP 1-38, is a potent
pharmacological antagonist of PAC1 receptor [22]. PACAP 6-38
has also been referred to as an antagonist of VPAC2 receptor [23].
Binding of PACAP hormones to their receptors preferentially
stimulates adenylate cyclase and increases the concentration of
intracellular cAMP. PACAP signalling also utilises other intracel-
lular messengers and pathways including calcium, phospholipase
D or diacylglycerol (DAG) and may consequently induce or inhibit
the activation of diverse signalling processes that regulate
proliferation, gene expression or cytosolic Ca2+ concentration of
various cell types [24]. The increased level of cAMP can activate
protein kinase A (PKA), which may augment CREB phosphor-
ylation e.g. in neuronal cells [25].
During inflammatory diseases of articular cartilage, a consider-
able amount of reactive oxygen species (ROS) is liberated [26].
ROS secretion by chondrocytes in turn may cause structural and
functional changes in the extracellular matrix (ECM) of hyaline
cartilage [27,28]. The elevated production of ROS is one of the
key factors triggering the induction of apoptosis that leads to
chondrocyte loss [29]. The downstream targets of ROS-induced
cell responses have been extensively studied in chondrocytes
[30,31] or in synoviocytes [32], but only a few pharmacological
compounds, such as thioredoxin and erdosteine, have been
identified so far as potent oxidative stress-preventing agents [33].
However, PACAP signalling and its anti-oxidative effects have not
been studied during in vitro chondrogenesis.
A well-reproducible in vitro experimental model for hyaline
cartilage differentiation is the chondrifying high density mesen-
chymal cell culture system (HDC), established from chondropro-
genitor cells isolated from limb buds of early chicken embryos in
the Hamburger–Hamilton developmental stage 22–24 [34,35]. In
HDC, chondrogenesis occurs spontaneously in six days, and a
considerable amount of metachromatic cartilage matrix can be
detected by the end of the culturing period. Differentiation of
chondrocytes is a complex process. An important initial step of
either in vivo or in vitro chondrogenesis is rapid proliferation [36]
and migration of chondroprogenitor cells that bring about
precartilaginous cell aggregates. This process occurs during the
first two culturing days in HDC, followed by final commitment of
chondrogenic cells on day 3 of culturing, which is characterised by
activation of genes encoding cartilage-specific ECM macromole-
cules, e.g. type II collagen or aggrecan core protein. In parallel to
the intracellular changes, differentiating chondrogenic cells start to
secrete a cartilage-specific matrix abundant in sulphated glycos-
aminoglycans (GAGs) and collagen type II. Chondrocyte differ-
entiation is regulated by several transcription factors; CREB and
Sox9 are required for the transcription of mRNAs for collagen
type II and aggrecan core protein (reviewed in [37]). Activity of
either CREB or Sox9 is triggered or enhanced by transient Ser/
Thr phosphorylation; moreover, Sox9 protein expression has a
peak on days 2–3 of culturing in HDC [38]. Several protein
kinases such as PKA, protein kinase C or MAP kinases are known
to phosphorylate both transcription factors [39,40]. According to
our previous findings in chondrogenic cells, the reversibility of this
modification is accomplished by PP2A [36] and/or calcineurin
(PP2B) [31].
PP2B is a Ser/Thr specific Ca2+-calmodulin dependent
phosphoprotein phosphatase (PP) consisting of a catalytic subunit
and a regulatory subunit, which effectively binds four Ca2+ ions on
its calcium-binding site, while the catalytic subunit harbours a
calmodulin binding region. As rise in free cytosolic Ca2+
concentration may result in activation of calcineurin, this PP is
an important effector of Ca2+-dependent signal transduction
pathways [41]. Calcineurin is reported to be a positive regulator
of chondrogenesis via the activation of nuclear factor of activated
T cells-4 (NFAT4); moreover, it has been found to be a key
mediator of oxidative stress-induced signalling in chondrogenic
cells [31,42].
The major goal of the present study was to identify elements
and putative role of PACAP signalling in differentiating chondro-
genic cells and to investigate the possibility that PACAP exerts
chondroprotective effects during oxidative stress. Here we report
that chondrogenic cells express components of PACAP signalling
and give evidence for a positive role of PACAP in the regulation of
in vitro chondrogenesis under physiological circumstances and
during oxidative stress. We propose calcineurin as a mediator of
the chondrogenesis-promoting effect of PACAP-signalling and we
prove that this enzyme also plays role in PACAP-related
protection of chondrogenesis in oxidative stress. Interestingly,
PACAP 6-38 was not found to be acting as an antagonist of
PACAP-signalling in our chondrogenesis model.
Materials and Methods
1. Cell culturing
Ross hybrid chicken embryos of Hamburger–Hamilton stages
22–24 were used to establish primary micromass chondrifying
mesenchymal cell cultures. Distal parts of the limb buds of
embryos were removed and a single-cell suspension of chondro-
genic cells at a density of 1.56107 cells/mL was yielded. Droplets
of different volumes of the cell suspension were inoculated into
Petri dishes or plates (Orange Scientifique, Braine-l’Alleud,
Belgium). Day of inoculation was considered as day 0. Colonies
were fed Ham’s F12 medium (Sigma, St. Louis, MO, USA),
supplemented with 10% foetal calf serum (Lonza Group Ltd,
Basel, Switzerland) and were kept at 37uC in the presence of 5%
CO2 and 80% humidity in a CO2 incubator. The medium was
changed on every second day. Cultures were maintained for 6
days.
2. Administration of PACAP polypeptides and/or H2O2,
CSA on various days of culturing
PACAP 1-38 at 100 nM and 10 mM (stock solution: 100 mM,
dissolved in sterile distilled water) was used as agonist of PAC1
receptor; as an antagonist, PACAP 6-38 at 100 nM, 1 mM and
10 mM (stock solution: 10 mM, dissolved in sterile distilled water)
was applied continuously from day 1. Synthetic PACAPs were
provided by Ga´bor To´th, Department of Medical Chemistry,
University of Szeged, Faculty of Medicine. To induce oxidative
stress, H2O2 was applied at 4 mM for 20 min on day 3 of
culturing. Calcineurin activity was inhibited with 2 mM cyclo-
sporine A (CSA; Sigma; stock solution: 2 mM, dissolved in
DMSO) applied continuously from day 1.
3. Light microscopical morphology
HDC established from 30 mL droplets of the cell suspension of
different experimental groups were cultured on round coverslips
(Menzel-Gla¨ser, Menzel GmbH, Braunschweig, Germany) placed
into 24-well culture plates. On day 6, cell cultures were fixed in a
4:1 mixture of absolute ethanol and 40% formaldehyde and
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stained with 0.1% dimethyl methylene blue (DMMB, Aldrich,
Germany) dissolved in 3% acetic acid. Photomicrographs of
metachromatic cartilaginous nodules were taken with Spot
Advanced camera on a Nikon Eclipse E800 microscope (Nikon
Eclipse 800, Tokyo, Japan). The amount of sulphated matrix
components was determined with a semiquantitative method by
measuring the optical density of extracted toluidine blue (TB,
Reanal, Budapest, Hungary) bound to GAGs in mature HDC as it
was described previously [43].
4. Hyaluronan detection
Cells of HDC were inoculated on the surface of coverslips as
described previously. Cells were fixed in Saint-Marie fixative for
1 h. After washing in 70% alcohol, nonspecific binding sites were
blocked in phosphate buffered saline with 0.1% Tween 20 (PBST)
supplemented with 1% bovine serum albumin (BSA, Amresco,
Solon, OH, USA) at 37uC. Hyaluronic acid (HA) was detected by
using a biotinylated HA-binding complex in 5 mg/mL concentra-
tion (bHABC, kindly provided by R. Tammi and M. Tammi,
Department of Anatomy, University of Kuopio, Kuopio, Finland)
at 4uC overnight. The reaction was visualised with Streptavidin-
Alexa555 (2 mg/mL, Invitrogen Corporation, Carlsbad, CA, USA)
for fluorescence microscopy. Cultures were mounted in Vecta-
shield Hard Set mounting medium (Vector Laboratories, Ltd.
Peterborough, UK) containing DAPI to visualise the nuclei of
cells. Cultures were viewed by fluorescence microscopy (Nikon
Eclipse E800). For investigation of proper reactivity, saturation of
bHABC with human (Sigma) and Streptomyces (Sigma) derived
HA was performed prior to the application of the HA-probe to the
cell cultures. Neither signals nor background were observed (data
not shown). All images were acquired using constant camera
settings to allow comparison of staining intensities.
5. Cell proliferation and viability assays
Ham’s F12 medium containing 1 mCi/mL 3H-thymidine
(diluted from methyl-3H-thymidine; 185 GBq/mmol, Amersham
Biosciences, Budapest, Hungary) was added to wells of special
opaque 96-well microtiter plates (Wallac, PerkinElmer Life and
Analytical Sciences, Shelton, CT, USA) for 16 h on day 3. For
cultures exposed to oxidative stress, this procedure was started
promptly after the 20-min-long treatment by H2O2. Colonies were
fixed with ice-cold 5% trichloroacetic acid, air-dried for 1 week
and radioactivity was counted by Chameleon liquid scintillation
counter (Chameleon, Hidex, Turku, Finland).
For investigation of cellular viability mitochondrial activity was
tested with MTT-assay. Cells cultured in 96-well plates were used,
10 mL MTT reagent (3-[4,5-dimethylthiazolyl-2]-2,5-diphenylte-
trazolium bromide; 25 mg MTT/5 mL PBS) was pipetted into
each well immediately or 16 h after oxidative stress. Cells were
incubated for 2 h at 37uC and following addition of 500 mL MTT
solubilising solution, absorption of samples was measured at
570 nm (Chameleon, Hidex).
6. RT-PCR analysis
Cell cultures were dissolved in Trizol (Applied Biosystems,
Foster City, CA, USA), and after the addition of 20% RNase free
chloroform samples were centrifuged at 4uC at 10,0006g for
15 min. Samples were incubated in 500 mL of RNase-free
isopropanol at 220uC for 1 h then total RNA was harvested in
RNase free water and stored at 220uC. The assay mixture for
reverse transcriptase reaction contained 2 mg RNA, 0.112 mM
oligo(dT), 0.5 mM dNTP, 200 units of High Capacity RT
(Applied Bio-Systems) in 16 RT buffer. For the sequences of
primer pairs and further details of polymerase chain reactions, see
Table 1. Amplifications were performed in a thermal cycler
(Labnet MultiGeneTM 96-well Gradient Thermal Cycler; Labnet
International, Edison, NJ, USA) in a final volume of 25 mL
(containing 1 mL forward and reverse primers [0.4 mM], 0,5 mL
dNTP [200 mM], and 5 units of Promega GoTaqH DNA
polymerase in 16 reaction buffer) as follows: 95uC, 2 min,
followed by 35 cycles (denaturation, 94uC, 1 min; annealing at
optimised temperatures as given in Table 1 for 1 min; extension,
72uC, 90 sec) and then 72uC, 10 min. PCR products were
analysed by electrophoresis in 1.2% agarose gel containing
ethidium bromide. GAPDH was used as internal control. Optical
density of signals was measured by using ImageJ 1.40 g freeware
and results were normalised to the optical density of untreated
control cultures.
7. Preparation of cell extracts
Cell cultures were washed in physiological NaCl solution and
were harvested. After centrifugation, cell pellets were suspended in
100 mL of homogenization buffer containing 50 mM Tris–HCl
buffer (pH 7.0), 10 mg/mL Gordox, 10 mg/mL leupeptine, 1 mM
phenylmethylsulphonyl-fluoride (PMSF), 5 mM benzamidine,
10 mg/mL trypsin inhibitor as protease inhibitors. Samples were
stored at 270uC. Suspensions were sonicated by pulsing burst for
30 sec at 40 A (Cole-Parmer, Illinois, USA). For Western blotting,
total cell lysates were used.
8. Western blot analysis
Samples for SDS–PAGE were prepared by the addition of
fivefold concentrated electrophoresis sample buffer (20 mM Tris–
HCl pH 7.4, 0.01% bromophenol blue dissolved in 10% SDS,
100 mM b-mercaptoethanol) to cell lysates to set equal protein
concentration in samples, and boiled for 10 min. About 70–80 mg
of protein was separated by 7,5% SDS-PAGE gel for detection of
PAC1, Sox9, P-Sox9, PKA, PP2B, NFAT4, GAPDH, HAS1,
HAS2, HAS3, Aggrecan, Collagen type II, Chst11, CREB and P-
CREB. Proteins were transferred electrophoretically to nitrocel-
lulose membranes. After blocking with 5% non-fat dry milk in
PBST (containing 0.1% Tween 20), membranes were washed and
exposed to the primary antibodies overnight at 4uC. Polyclonal
anti-Sox9 antibody (Abcam, Cambridge, UK) in 1:600, polyclonal
anti-P-Sox9 antibody (Sigma) in 1:800, polyclonal anti-PAC1
antibody (Sigma) in 1:400, polyclonal anti-PKA antibody (Cell
Signaling, Danvers, MA, USA) in 1:600, polyclonal anti-PP2B
antibody (Cell Signaling) in 1:600, polyclonal anti-NFAT4
antibody (Cell Signaling) in 1:400, polyclonal anti-HAS1 (Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) in 1:200,
polyclonal anti-HAS2 (Santa Cruz Biotechnology Inc.) in 1:200,
polyclonal anti-HAS3 (Abcam) in 1:400, polyclonal anti-Aggrecan
(Millipore, Billerica, MA, USA) in 1:400, monoclonal anti-
Collagen type II (Chemicon-Millipore) in 1:200, polyclonal anti-
Chst11 (Sigma) in 1:400, polyclonal anti-CREB antibody (Milli-
pore) in 1:800, polyclonal anti-P-CREB antibody (Millipore) in
1:800 dilution and anti-GAPDH antibody (Abcam) in 1:1000 were
used. After washing for 30 minutes in PBST, membranes were
incubated with anti-rabbit IgG (Bio-Rad Laboratories, CA, USA)
in 1:1500, anti-mouse IgG (Bio-Rad Laboratories) in 1:1500 or
anti-goat IgG (Sigma) in 1:2000 dilution. Signals were detected by
enhanced chemiluminescence (Millipore) according to the instruc-
tions of the manufacturer. Signals were manually developed on X-
ray films. Optical density of Western blot signals was measured by
using ImageJ 1.40 g freeware and results were normalised to that
of untreated control cultures.
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Table 1. Nucleotide sequences, amplification sites, GenBank accession numbers, amplimer sizes and PCR reaction conditions for
each primer pair are shown.
Gene Primer Nucleotide sequence (59R39) GenBank ID
Annealing
temperature
Amplimer size
(bp)
Aggrecan core protein sense CAA TGC AGA GTA CAG AGA XM_001232949 54uC 429
(276–294)
(Agr1) antisense TCT GTC TCA CGG ACA CCG
(688–704)
Chst11 sense GGT TTT GAC GGG AAG AGG C XM_416316 56uC 413
(957–975)
antisense CGT AGT GAA TGT GGC AAG GGT
(1349–1369)
Collagen II sense GGA CCC AAA GGA CAG ACG G NM_204426 59uC 401
(1191–1210)
(Col2a1) antisense TCG CCA GGA GCA CCA GTT
(1573–1591)
CREB sense GCT ATT ACG CAA GGA GGA NM_204450 48uC 114
(725–742)
antisense AAT GGT AGT GCC AGG TTG
(821–838)
Extl1 sense CCA AGG CAG CCA TCG TAG NM_004455 54uC 289
(1808–1825)
antisense CCT GAT TAT CTT CCC TTC TA
(2075–2096)
HAS1 sense CCT ACG AGG CGG TGG TCT NM_001523 56uC 306
(1240–1257)
antisense GCA GAG GGA CGT AGT TAG CG
(1526–1545)
HAS2 sense GAG ACG ACA GGC ATC TAA CTA AC AF_106940 52uC 330
(1497–1519)
antisense AAG ACT TTA TCA GGC CCA CTA A
(1805–1826)
HAS3 sense ATT GCC ACC GTC ATC CAG XM_425137 60.4uC 479
(826–843)
antisense ACC TCG GCG AAG ACC AAC
(1287–1304)
NFAT4 sense AGC CAG TAT TGA TTG TGC NM_173165 46uC 354
(1912–1929)
(NFATc3) antisense CCTGATTATCTTCCCTTCTA
(2246–2265)
PAC1 sense GTC AGA CAA CCA GGA TTA C NM_001098606 49uC 141
(435–453)
(ADCYAP1R1) antisense TGG ATA AAG TTC CGA GTG
(559–575)
PKA sense GCA AAG GCT ACA ACA AGG C NM_008854 53uC 280
(847–865)
(Prkaca) antisense ATG GCA ATC CAG TCA ATC G
(1109–1126)
PP2B sense CTG CTC TGA TGAA CCA ACA GTT XM_420664 54uC 504
(647–668)
(PPP3CA) antisense ACG GCA AGG ACC AGG TAA ACA
(1130–1150)
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9. Calcineurin activity assay
For in vitro calcineurin activity assays, cells were harvested in
homogenization buffer and suspensions were sonicated by pulsing
burst on ice for 30 sec at 40 A (see above). After centrifugation at
10,0006g for 10 min at 4uC, supernatants with equal protein
concentrations were used for enzyme activity measurements.
Activity of calcineurin was assayed by using RII phosphopeptide
substrate, and the release of free PO4 was detected by a classic
malachite green assay (Abcam). Measurements were performed
according to the instructions of the manufacturer in three
independent experiments.
10. Determination of cytosolic free Ca2+ concentration
Measurements were performed on day 3 and 16 h later on day
4 on cultures seeded onto 30 mm round coverslips using the
calcium-dependent fluorescent dye Fura-2 as described previously
[43]. Fura-2-loaded cells were placed on the stage of an inverted
fluorescent microscope (Diaphot, Nikon, Kowasaki, Japan) and
viewed using a 406 oil immersion objective. Measurements were
carried out in Tyrode’s salt solution (containing 1.8 mM Ca2+;
composition: 137 mM NaCl, 5.4 mM KCl, 0.5 mM MgCl2,
1.8 mM CaCl2, 11.8 mM HEPES, 1 g/L glucose; pH 7.4) in a
perfusion chamber using a dual wavelength monochromator
equipment (DeltaScan, Photon Technologies International, Law-
renceville, KY, USA) at room temperature. Excitation wavelength
was altered between 340 and 380 nm at 50 Hz and emission
wavelength was detected at 510 nm. Data acquisition frequency
was 10 Hz. Ratios of emitted fluorescence intensities (detected at
alternating excitation wavelengths; F340/F380) were measured as
previously described [43]. Cytosolic Ca2+ concentration was
determined on day 3 directly after PACAP and/or H2O2
administration and 16 h later on day 4. Intracellular Ca2+ levels
in cells of untreated control cultures were determined in 3
independent experiments, measuring 30 cells in each case.
11. Statistical analysis
All data are representative of at least three independent
experiments. Where applicable, data are expressed as mean 6
SEM. Statistical analysis was performed by One Way ANOVA
test combined with post hoc tests. Where ANOVA reported
significant differences among the groups (P,0.05) a post hoc test
(multiple comparison versus control group, Dunnett’s method) was
used to isolate the groups that differed from the control group at
p,0.05. The respective control group was the untreated control
when comparison was made among control, H2O2-treated,
PACAP 1-38-treated and PACAP 6-38-treated groups, whereas
the H2O2-treated cultures were used as control in the post hoc test
when comparison was made among H2O2-treated, H2O2+PACAP
1-38-treated and H2O2+PACAP 6-38-treated samples. Statistical
analysis and comparison of Western blot and PCR results can be
seen in Figures S3A, S3B, S3C, S3D, S3E, S3F, S3G, S3H and
S3I.
Table 1. Cont.
Gene Primer Nucleotide sequence (59R39) GenBank ID
Annealing
temperature
Amplimer size
(bp)
Sox9 sense CCC CAA CGC CAT CTT CAA NM_204281 54uC 381
(713–731)
antisense CTG CTG ATG CCG TAG GTA
(1075–1093)
VPAC1 sense GTT CTA TGG CAC GGT CAA NM_001097523 52uC 216
(376–393)
(VIPR1) antisense AGC AAT GTT CGG GTT CTC
(573–590)
VPAC2 sense TCG GAA CTA CAT CCA TCT NM_001014970 48uC 177
(477–497)
(VIPR2) antisense TTT GCC ATA ACA CCA TAC
(636–653)
Xylt1 sense AGC GAT CCA ATT ACT TAC ACC XM_414904 52,5uC 407
(1103–1123)
antisense GAG AAA CCA ATC CGA CCC
(1492–1509)
Xylt2 sense TCC TGT CCA AAT ACC GAG ATA A NM_001001785 54uC 208
(1037–1058)
antisense ACC ACG TAC TGC ACG AAG C
(1226–1244)
GAPDH sense GAG AAC GGG AAA CTT GTC AT NM_204305 54uC 556
(238–258)
antisense GGC AGG TCA GGT CAA CAA
(775–793)
doi:10.1371/journal.pone.0091541.t001
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Results
1. Identification of PACAP and its receptors in
chondrifying cells
mRNA expressions of preproPACAP, as well as those of
PACAP receptors, i.e. PAC1, VPAC1 and VPAC2 were detected
throughout the 6-day-long culturing period in chicken HDC
(Figure 1A, Figure S3A). As PACAP has a 100-fold higher binding
affinity to the PAC1 receptor compared to VPAC receptors [21],
we only investigated the protein expression of PAC1 in this study.
Protein expression of the PAC1 receptor showed a peak-like
pattern with a five-fold elevation on days 1 and 2 (when
chondrogenic cells predominantly differentiate to chondroblasts)
compared to day 0 (Figure 1B, Figure S3B). Chicken brain lysate
was used as positive control.
2. Administration of PACAP proteins augments cartilage
formation
Continuous application of PACAP 1-38 at 100 nM or 10 mM
from day 1 of culturing equally elevated cartilage matrix
production by 20% compared to the control as revealed by
DMMB and TB staining procedures (Figure 2A, Figure S1).
Surprisingly, when PACAP 6-38, a potent antagonist of PAC1 and
VPAC2 receptors [22] was applied, we observed concentration-
dependent changes in metachromatic cartilage ECM formation:
while no change was caused by either 100 nM or 1 mM PACAP 6-
38 (Figure S1), a pronounced (1.5-fold) elevation of metachromatic
matrix production in HDC was measured when applied at 10 mM
(Figure 2A). Metachromatic staining allows approximation of the
amount of sulphated GAGs and PGs in the cartilage matrix and is
a good indicator of the effectiveness of chondrogenesis. However,
changes in the amount of the non-sulphated GAG hyaluronan
(HA) cannot be evaluated with this method. In order to monitor
effects of PACAPs on the presence of this ECM component HA
affinity assays were performed. Similar to what has been observed
following metachromatic staining procedures, applications of
PACAPs resulted in more intense fluorescent signals for HA. In
our multicellular cell cultures, fine details of the localization of HA
cannot be determined with this method, but an overall increase of
the HA-amount was well ascertainable (Figure 2B).
As far as the expression of cartilage-specific ECM components is
concerned, the mRNA level of Col2a1 (collagen type II) remained
steady under the effect of both PACAPs; in contrast, Agr1
(aggrecan core protein) was found to be slightly upregulated in
the presence of PACAP 6-38, while no change was detected by
PACAP 1-38 treatment (Figure 2C, Figure S3C). Sulphated GAGs
and PGs in cartilage ECM are synthesised and assembled by
several enzymes such as 1,4-N-acetylglucosaminyltransferase
(Extl1), chondroitin 4-O-sulfotransferase 1 (Chst11), xylosyltrans-
ferase 1 and 2 (Xylt1, Xylt2); therefore, the mRNA expressions of
these enzymes were also investigated. As an obvious elevation of
non-sulphated HA in cartilage ECM also was observed and HA
acts as a scaffold to which aggrecan monomers are bound to form
large aggregates, mRNA expression patterns of HA synthase
enzymes (HAS1, HAS2, HAS3) were also monitored. Under the
effect of PACAP 6-38, we detected moderate elevations in the
mRNA expression of Extl1, Chst11, Xylt2 and HAS2, while
administration of PACAP 1-38 slightly decreased the expression of
these enzymes, except for Xylt1 and HAS2, whose expression was
not significantly altered (Figure 2C, Figure S3C).
Investigation of protein expression of aggrecan and collagen
type II resulted in a pattern comparable to that of metachromatic
matrix production. Administration of PACAP 1-38 elevated
collagen type II expression and had an even stronger stimulatory
effect on aggrecan expression (Figure 2D, Figure S3D). Moreover,
the presence of PACAP 6-38 had a well-pronounced protein
expression-increasing effect on collagen type II and a smaller but
significant elevation of aggrecan expression was also detected
(Figure 2D). Enhanced Chst11 protein expression was shown in
the presence of the neuropeptides indicating augmented GAG
accumulation in the ECM of HDC. As a result of PACAP
treatments, the elevated protein expression of all three HAS
isotypes showed a good correlation with the results of HA-affinity
histochemistry (Figure 2B and D).
The increased amount of cartilage matrix can also be a
consequence of higher number of chondrogenic cells as a result of
more intense proliferation. Although the mitochondrial activity of
differentiating cells was not altered either on day 3 or 4 by PACAP
treatments as revealed by MTT assays, administration of both
PACAPs caused a significant increase in proliferation rate
(Figure 2E).
3. PACAP 1-38 and 6-38 exert protective function during
cartilage formation under oxidative stress
Oxidative stress was induced by the application of H2O2 at
4 mM for 20 min on the day of final commitment of chondrogenic
cells (day 3). In accordance with our previously published results
[31], ROS diminished the formation of metachromatic cartilage
Figure 1. Expression of preproPACAP and PACAP receptors in
chondrifying micromass cultures. For RT-PCR (A) and Western blot
(B) reactions, GAPDH was used as control. Optical density of signals was
measured and results were normalised to the optical density of 0-day-
old cultures. Representative data of 3 independent experiments. For
panels (A) and (B), numbers below signals represent integrated
densities of signals determined by ImageJ software.
doi:10.1371/journal.pone.0091541.g001
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nodules (Figure 2A) without causing any significant changes in
viability (Figure 2E) or apoptotic or necrotic processes of the
differentiating cells (Figure S2). When H2O2 was added to cultures
previously treated with PACAP 1-38 or PACAP 6-38, metachro-
matic cartilage matrix formation was at least partially rescued
(40% or 60% of untreated controls, respectively; Figure 2A). ROS
also decreased the HA content of ECM, but the application of
PACAP neuropeptides reduced the effect of oxidative stress
(Figure 2B). The mRNA expressions of Col2a1 and Agr1 were not
altered by the presence of ROS (Figure 2C, Figure S3C). In
contrast, the protein levels of collagen type II and aggrecan were
significantly decreased in the presence of H2O2, which was
prevented by both PACAP 1-38 and PACAP 6-38 (Figure 2D,
Figure S3D). The mRNA expressions of Extl1 and Chst11
decreased under oxidative stress, which was prevented by pre-
treatment with PACAPs (Figure 2C, Figure S3C). Furthermore,
the decrease in protein expression of Chst11 during oxidative
stress was prevented by PACAPs; moreover, it was intensified
compared to PACAP treated cultures (Figure 2D, Figure S3D).
Administration of PACAPs during oxidative stress resulted in a
slight elevation in the mRNA expression of Xylt1 and Xylt2.
Expressions of HAS1 and HAS2 were not altered significantly by
either H2O2 or PACAPs; on the contrary, the mRNA expression
of HAS3 significantly decreased under combined treatment with
PACAPs and ROS (Figure 2C, Figure S3C). Protein levels of all
HAS isoforms decreased under the effect of oxidative stress, which
was rescued by PACAP neuropeptides (Figure 2D, Figure S3D).
Next, we looked at how oxidative stress modulated cellular
proliferation of HDC and whether pretreatment with PACAPs
could attenuate these effects. 20-min-long treatment with H2O2 on
day 3 of culturing abrogated cellular proliferation, which was not
rescued when cultures were pretreated with PACAP 1-38
(Figure 2E). Interestingly, however, pretreatment with the
PAC1-antagonist PACAP 6-38 had a significant protective effect
against the proliferation inhibition caused by oxidative stress
(Figure 2E).
4. PACAP neuropeptides activate PKA, CREB and Sox9 in
chondrogenic cells
The ‘‘canonical’’ PACAP-signalling pathway involves the
activation of G-protein coupled PAC1 receptor and subsequent
elevation of intracellular cAMP concentration, which may lead to
the induction of downstream signalling cascades such as PKA
activation [44]. PKA is known to phosphorylate CREB and Sox9
transcription factors, which in turn can translocate into the nucleus
and may activate the expression of cartilage-specific ECM
molecules (e.g. collagen type II and/or core protein of aggrecan)
in chondrogenic cells [39,45]. In our experiments, PACAPs only
slightly influenced both the mRNA and the protein expression of
PKA; however, they rescued PKA protein expression after
treatment with H2O2 (Figure 3A–B, Figure S3E–F).
Addition of PACAP neuropeptides to HDC did not alter
significantly the mRNA and protein expression of CREB. The
elevation of CREB protein expression was more pronounced
during simultaneous application of PACAPs and H2O2. Although
oxidative stress alone significantly decreased both protein expres-
sion and phosphorylation level of CREB, the neuropeptides
rescued the phosphorylation-decreasing effect of ROS (Figure 3B,
Figure S3F).
Neither PACAP 1-38 nor PACAP 6-38 affected the mRNA
expression of Sox9 (Figure 3A). Nevertheless, both neuropeptides
markedly elevated its protein expression (Figure 3B, Figure S3E).
Phosphorylation of Sox9 on Ser 211 residue by PKA conveys
increased transcriptional activity [39]; we observed that the level of
P-Sox9 became elevated in the presence of both PACAPs
(Figure 3B). Moreover, the reduced expression and phosphoryla-
tion of Sox9 protein by oxidative stress was compensated by the
administration of PACAPs (Figure 3B, Figure S3F). The protein
expression of PAC1 receptor was significantly elevated under
oxidative stress and this phenomenon became more pronounced
in the simultaneous presence of PACAP neuropeptides (Figure 3B,
Figure S3F).
5. Calcineurin is a downstream target of PACAP-
signalling during chondrogenesis
PACAP signalling via PAC1 receptor activation can modulate
intracellular Ca2+ concentration [44]. In our experiments,
significant elevation of free cytosolic Ca2+ concentration was
measured in PACAP 1-38 treated cells either in normal conditions
or in oxidative stress, while PACAP 6-38 failed to cause any
significant alteration of this parameter (Figure 4). Nonetheless, the
above effects proved to be only temporary as Ca2+ levels in all
experimental groups returned to control levels when measured
16 h after treatments (Figure 4). It is worth mentioning that
chondrogenic cells in HDC are very sensitive to alterations of
resting cytosolic free Ca2+ concentration; elevation over a certain
threshold inhibits cartilage formation, while smaller increase exerts
chondrogenesis-promoting effect [43]. The Ser/Thr phosphopro-
tein phosphatase calcineurin is amongst the signalling molecules
that respond to changes of intracellular Ca2+ concentration.
Calcineurin is reported as a positive regulator of chondrogenesis
and is also involved in signalling mechanisms evoked by oxidative
stress in chondrogenic cells [31]. Expression of calcineurin
responded to treatment with PACAPs: although the mRNA
expression was not significantly altered (Figure 5A, Figure S3G),
protein expression of calcineurin was almost doubled by PACAP
1-38 and a more pronounced, nearly 3-fold stronger signal was
detected in the presence of PACAP 6-38 (Figure 5B, Figure S3H).
Figure 2. Effects of PACAP and/or H2O2 on matrix production, mitochondrial activity and proliferation rate of HDC. PACAP 1-38 at
100 nM, PACAP 6-38 at 10 mM were applied continuously from day 1. (A) Metachromatic cartilage areas in 6-day-old cultures were visualized with
DMMB dissolved in 3% acetic acid. Metachromatic (purple) structures represent cartilaginous nodules formed by many cells and cartilage matrix rich
in sulphated GAGs and PGs. Original magnification was 46. Scale bar, 500 mm. Optical density (OD625) was determined in samples containing TB
extracted with 8% HCl dissolved in absolute ethanol. (B) HA production of HDC was determined by HA affinity reaction. Red fluorescence represents
HA in ECM of a representative cartilage nodule on day 6 of culturing. Original magnification was 406. Scale bar, 20 mm. (C) RNA expression of
aggrecan core protein (Agr1), collagen type II (Col2a1), chondroitin 4-O-sulfotransferase 1 (Chst111), 1,4-N-acetylglucosaminyltransferase (Extl1),
xylosyltransferase 1 and 2 (Xylt1 and Xylt2), and HAS1, HAS2 and HAS3 on day 3. GAPDH was used as a control. (D) Protein expression of aggrecan
core protein, collagen type II, chondroitin 4-O-sulfotransferase 1 (Chstl 11), HAS1, HAS2 and HAS3 on day 3. GAPDH was used as a control. (E) Effects
of PACAP and/or H2O2 administration on mitochondrial metabolic activity and cellular proliferation in HDC on culturing day 3. Asterisks indicate
significant (*P,0.05) alteration of cell proliferation or matrix production as compared to the respective control; hash signs indicate significant
(#P,0.05) difference in proliferation rate and cartilage formation as compared to the respective H2O2 treatment. For panels (C) and (D) numbers
below signals represent integrated densities of signals determined by ImageJ software. Representative data of 3 independent experiments are
shown. (C, control; P1-38, PACAP 1-38; P6-38, PACAP 6-38).
doi:10.1371/journal.pone.0091541.g002
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Oxidative stress caused a significant decrease in the expression of
calcineurin, and application of PACAPs prevented this effect
(Figure 5B, Figure S3H). Activity of calcineurin was elevated by
both PACAPs (Figure 5C), while oxidative stress lowered this
parameter and administration of the neuropeptides exerted
protective effect against this inhibition (Figure 5C). One of the
downstream targets of PP2B is NFAT4. Although mRNA
expression of this transcription factor showed a significant increase
evoked only by PACAP 6-38, significant elevations of NFAT4
protein expression were detected after administration of both
PACAPs (Figure 5A–B, Figure S3G–H). Moreover, both neuro-
peptides exerted a protecting effect against the negative influence
of H2O2 on NFAT4 expression (Figure 5A–B). Further scrutinis-
ing the role of calcineurin in PACAP signalling we inhibited the
activity of calcineurin by CSA, a pharmacological inhibitor of this
phosphatase. Following application of CSA, a dramatic decrease
in the metachromatic staining of the cell cultures was visible as a
result of the chondro-inhibitory effect of this pharmacon and
PACAPs failed to rescue cartilage formation under this condition
(Figure 6A). Administration of CSA decreased the proliferation
rate of chondrogenic cells. The presence of PACAP neuropeptides
attenuated the antiproliferative effect of calcineurin inhibition, but
proliferation rate still remained very low compared with controls
or cultures treated with CSA (Figure 6B). The mRNA expressions
of Agr1, Col2a1 and Sox9 were decreased after CSA administra-
tion, and PACAPs failed to compensate this effect of the inhibition
of calcineurin activity (Figure 6C, Figure S3I).
Discussion
The presence and functions of PACAP neuropeptides are
broadly investigated in various peripheral tissues such as kidney,
liver and testis, but little is known about its distribution in cartilage
[9,46]. Since PACAP is known as an important protective
compound during various cellular stress responses
[4,14,16,47,48], it could be intriguing whether it influences
noxious effects of oxidative stress during cartilage formation or
regeneration. Quite recently, migratory chondroprogenitor cells,
which may offer regeneration of the damaged tissue to a certain
extent, have been isolated from osteoarthritic human articular
cartilage [49]. Therefore, any endogenous mechanism to enhance
the chondrogenic potential of this unique cell population may have
high impact on the healing process.
Here we report the presence and function of the PACAP-
signalling toolkit in differentiating chicken chondrocytes and
provide evidence for a positive regulatory role of this neuropeptide
on chondrogenesis in vitro. To our best knowledge, this report is the
first to demonstrate the presence of preproPACAP mRNA in
chondrogenic cells. We were also able to show that mRNAs of all
PACAP receptors are expressed by differentiating chondrocytes.
In other skeletal elements such as bone, the expression of PACAP
receptors (PAC1, VPAC1 and VPAC2) has already been
published [50]. Activation of PACAP receptors has also been
investigated in an osteoblast cell line [51]. Of the receptors where
PACAP may act as a ligand, PAC1 exhibits the highest affinity to
PACAP [21]; therefore, we confirmed the protein expression of
this receptor in differentiating chondrocytes. Similar to several
other plasma membrane-related signalling molecules involved in
the regulation of chondrogenesis in HDC such as the P2X4
purinoreceptor [52] or the voltage gated potassium channel KV1.1
[53], protein expression of PAC1 receptor also showed a peak on
day 3 of culturing, when final commitment of chondrogenic cells
occurs in HDC. This finding indicated that PACAP signalling
might have a role in this step of chondrogenesis. This idea was
supported by reports on a differentiation-promoting effect of
PACAP 1-38 in neuronal stem cell development [12,54] or in the
formation of the reproductive system [55]. Indeed, addition of the
Figure 3. PACAP and oxidative stress influence PKA, CREB,
Sox9 and PAC1 receptor expression in chondrogenic cells.
PACAP 1-38 at 100 nM, PACAP 6-38 at 10 mM were administrated
continuously from day 1. mRNA (A) and protein (B) expression of PKA,
CREB, P-CREB, Sox9, P-Sox9 and PAC1 in cells of chondrifying micromass
cultures on day 3 of culturing. For RT-PCR and Western blot reactions,
GAPDH was used as internal control. Optical density of signals was
measured and results were normalised to the optical density of internal
controls. For panels (A) and (B) numbers below signals represent
integrated densities of signals determined by ImageJ software. Asterisks
indicate significant (*P,0.05) alteration of expression as compared to
the respective control; hash signs indicate significant (#P,0.05)
difference in expression as compared to the respective H2O2 treatment.
Representative data of 3 independent experiments. (C, control; P1-38,
PACAP 1-38; P6-38, PACAP 6-38).
doi:10.1371/journal.pone.0091541.g003
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PAC1 agonist PACAP 1-38 into the medium of chondrifying cell
cultures enhanced cartilage formation. Although PACAP 6-38 has
been referred to as an antagonist [56] of PAC1/VPAC2 receptors,
when administrated at 10 mM a more pronounced cartilage
formation-promoting effect was observed compared to PACAP 1-
38 applied at the concentration of 100 nM or 10 mM. The
‘‘inverse’’ effect of PACAP 6-38; that is, it acts as an agonist, rather
than an antagonist has also been observed by others; there is
evidence that it can also act as a PACAP receptor agonist in
distantly related tissues such as sensory nerve terminals, glial cells
and cytotrophoblasts [57–58].
In spite of the pronounced elevation in the amount of cartilage
matrix under the effect of PACAPs, mRNA expression level of
aggrecan core protein only exhibited a slight change in the
presence of PACAP 6-38; moreover, mRNA expressions of
matrix-synthesizing enzymes were also altered by PACAP 6-38
only. Surprisingly, the application of PACAP 1-38 did not
significantly modulate the mRNA expressions of any of the
enzymes mentioned above. In contrast to the protein expression of
ECM components such as aggrecan, collagen type II expression
was found to be significantly elevated in the presence of both
neuropeptides, and similar results were observed for extracellular
HA accumulation and HAS enzyme expression patterns. Similarly
to our data, others also failed to demonstrate any striking effects of
PACAP treatments on gene expression levels along with consid-
erable changes in protein levels and/or phosphorylation of the
same molecules: Moody et al. reported that the activation of PAC1
receptor with addition of PACAP regulated the tyrosine
phosphorylation of FAK rather than significantly influence mRNA
expression of these molecules [59]. Furthermore, it has also been
shown that PACAP can modulate the expression levels of 120
independent proteins in megakaryocytes without interfering with
mRNA expression levels [60]. When we looked at the expression
of Sox9, the master transcription factor of chondrogenesis [37], we
failed to detect any significant change in its mRNA level again.
Nonetheless, Sox9 protein expression was elevated by either
PACAP 1-38 or PACAP 6-38, and a similar increase in Sox9
phosphorylation status was also found. These observations raise
the possibility that PACAPs augment chondrogenesis and stimu-
late matrix production via influencing translation or protein
degradation, rather than modulating transcriptional events.
The first steps of proper cartilage differentiation are also
determined by rapid increase in cell number; therefore, the
proliferation rate of chondrogenic cells was also investigated. We
detected a highly elevated proliferation rate under the effect of
PACAPs, which may have significant contribution to the
augmented cartilage formation without significant upregulation
in transcription of genes encoding matrix molecules and/or their
synthesizing enzymes. Nonetheless, the effect of PACAP on cell
proliferation is cell type and tissue dependent, since it is known to
induce cell division of smooth muscle cells in blood vessels [61] or
astrocytes [12], but inhibited the proliferation of retinal progenitor
cells [62] and certain tumour cells [63].
The efficient protective role of PACAP in various cellular stress
situations has also been widely demonstrated [14,16,47]. During
inflammatory processes of joints, the accumulation of ROS around
and probably within articular cartilage can negatively influence
the normal composition of the ECM and may induce apoptosis of
chondrocytes in vivo. In a good correlation with this, our group has
reported a severe reduction of in vitro cartilage formation during
H2O2-induced oxidative stress [31]. Among the pleiotropic effects
of PACAP it is well demonstrated that it can prevent the apoptotic
Figure 4. Administration of PACAPs and/or H2O2 influences Ca
2+ homeostasis of chondrogenic cells. PACAP 1-38 at 100 nM, PACAP 6-
38 at 10 mM were administrated continuously from day 1. Basal cytosolic Ca2+ concentration in Fura-2-loaded cells of HDC on days 3 and 4 of
culturing. Measurements were carried out in untreated control cultures, during PACAP treatment or directly after oxidative stress. Data shown are
mean values of 30 cells in each experimental group. Asterisks indicate significant (*P,0.05) alterations of cytosolic Ca2+ concentration as compared to
the respective control; hash signs indicate significant (#P,0.05) difference in cytosolic Ca2+ concentration as compared to the respective H2O2
treatment. Shown are representative results of 3 independent experiments. (C, control; P1-38, PACAP 1-38; P6-38, PACAP 6-38).
doi:10.1371/journal.pone.0091541.g004
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effect of ROS in astrocytes [19]. The trophic function of PACAP
has also been shown in various peripheral tissues such as epithelial
cells of kidney [18], endothelial cells [48] and cardiomyocytes [64].
In HDC, we applied 4 mM H2O2 to evoke oxidative stress during
chondrogenesis. This concentration was not cytotoxic [31], but
diminished cartilage formation. Pre-treatment with PACAPs
partially rescued cartilage formation in H2O2-treated HDC. This
chondro-protective effect of PACAPs during oxidative stress
seemed multifactorial: pretreatment with PACAPs rescued Sox9
protein expression and phosphorylation, prevented reduction of
HA synthesis and/or aggrecan and collagen type II expression and
it also compensated the antiproliferative effect of oxidative stress.
Interestingly, PACAP 6-38 exerted an even more pronounced
protective effect. As several structural variants of PAC1 receptor
with different downstream effectors have been described [65–67],
the above-described broad spectrum of protecting effect of
PACAPs might be the consequence of the fact that distinct
downstream signal transduction pathways became activated by the
two different neuropeptides via binding to different isoforms of
PAC1 receptor.
Binding of PACAP to PAC1 receptor generally leads to an
increase of intracellular cAMP concentration that triggers the
activation of PKA, PKC or MAPK pathways [44]. In the current
study, PACAP neuropeptides, at least partly, exerted their effects
by acting via the ‘‘canonical’’ PKA-related signal transduction
pathway in chondrogenic cells: their administration to the cell
cultures significantly elevated the protein expression of PKA.
Major downstream targets of the PKA pathway in chondrogenic
cells can be the transcription factors Sox9 [39] or CREB [68].
Sox9 can establish a direct interaction with CREB [45], implying
the possibility of their parallel activation during chondrogenesis.
Indeed, the protein expression and the ratio of the active
phosphorylated form of both CREB and Sox9 were increased
under the effect of PACAPs. The applied oxidative stress regime
decreased the protein expression of PKA, CREB, Sox9 and
lowered the phosphorylation level of both transcription factors.
The increased protein expression of PAC1 receptor is an
interesting phenomenon; however, similar results were observed
in rat carotid body under hypoxic conditions [69] or in global
brain ischemia in mice [70]; it may be a general cellular response
to allow an enhanced PACAP signalling in order to obtain a more
efficient cellular protection.
Calcineurin is a positive modulator of chondrogenesis and is a
target of oxidative stress in HDC [31,42]. Our laboratory has
demonstrated that pharmacological inhibition of calcineurin with
CSA diminished cartilage formation, although the overexpression
of the catalytic subunit of this phosphatase also decreased cartilage
formation [71], suggesting the importance of the maintenance of
calcineurin activity between precisely set levels during chondro-
genesis. We have also published that the activity of calcineurin
significantly decreased during oxidative stress in a ROS-dose
dependent manner and played role in the inhibition of cartilage
formation [31]. As PAC1 receptor can regulate cytosolic Ca2+
concentration via elevation of cAMP concentration [72], we also
aimed to explore whether PACAP exerted any effects on the
activity of calcineurin in chondrogenic cells. We found that
intracellular Ca2+ concentration of chondrogenic cells was
influenced by these neuropeptides. In line with this, both protein
expression and activity of calcineurin markedly increased in the
presence of PACAPs. Moreover, PACAPs were able to prevent the
PP2B activity-reducing effect of oxidative stress. One of the
downstream targets of PP2B can be NFAT4, which promotes
chondrogenesis via the induction of BMP signalling pathways [73].
Indeed, the positive effect of PACAP on calcineurin activity in
chondrogenesis was further supported by the elevated NFAT4
protein expression in HDC, which can partly be responsible for
the enhanced cartilage formation. The above results suggest that
PACAPs influence multiple signalling pathways in chondrogenic
cells: the canonical PKA-pathway and the calcineurin–NFAT–
BMP axis can both play role. The significance of the latter
signalling pathway was underlined by our observation that
pharmacological inhibition of calcineurin activity by CSA
diminished cartilage formation [31] and application of PACAPs
failed to rescue chondrogenesis in this experimental condition.
Figure 5. Effects of PACAPs and/or oxidative stress on NFAT4,
calcineurin expression and activity in chondrifying cells. PACAP
1-38 at 100 nM, PACAP 6-38 at 10 mM were applied continuously from
day 1. (A) mRNA and (B) protein expression of PP2B and NFAT4 in HDC
on day 3 of culturing. GAPDH was used as a control. Numbers below to
the signals represent integrated densities of signals determined by
ImageJ software. (C) Enzyme activity of calcineurin in chondrifying cells
on day 3. Asterisks indicate significant (*P,0.05) decrease of calcineurin
activity and expression as compared to the respective control; hash
signs represent significant (#P,0.05) decrease of calcineurin activity
and expression as compared to the respective H2O2 treatment.
Representative data of 3 independent experiments. (C, control; P1-38,
PACAP 1-38; P6-38, PACAP 6-38).
doi:10.1371/journal.pone.0091541.g005
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Figure 6. Effects of PACAPs on cartilage formation of HDC when calcineurin was inhibited with cyclosporine A (CSA). CSA at 2 mM
was administered continuously from day 1 of culturing with or without PACAPs. (A) Metachromatic cartilage areas in 6-day-old cultures were
visualized with DMMB dissolved in 3% acetic acid. Metachromatic (purple) areas represent cartilaginous nodules formed by many cells and cartilage
matrix rich in sulphated GAGs and PGs. Original magnification was 46. Scale bar, 500 mm. Optical density (OD625) was determined in samples
containing TB extracted with 8% HCl dissolved in absolute ethanol. (E) Effects of PACAP and/or CSA on cellular proliferation in HDC on culturing day
3. (C) RNA expression of collagen type II (Col2a1), aggrecan core protein (Agr1) and Sox9 on day 3. GAPDH was used as a control. Representative data
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Furthermore, the application of PACAP neuropeptides was not
able to prevent either the severe impairment of cell proliferation or
the mRNA expression of cartilage specific molecules when
calcineurin was inhibited with CSA. These data further support
our concept that calcineurin is a downstream target of PACAP
signalling. Indeed, it has been demonstrated the PACAP addition
exerted nephroprotective effect during CSA administration in
kidneys of mice [74].
Our finding that both PACAP-treatments and oxidative stress
resulted in elevated cytosolic Ca2+-concentration further compli-
cates the picture. We have reported that during the course of
chondrogenesis there was a characteristic pattern in cytosolic
Ca2+-concentration in chondrogenic cells with a peak at day 3,
which pattern was indispensable to proper cartilage formation
[43]. Ca2+-concentration detected in 3-day-old cells of HDC
treated either with PACAP 1-38 or H2O2 was higher (approxi-
mately 160 and 180 mM, respectively) than the precisely regulated
Ca2+-level of control cells (around 140 mM). In contrast, the
administration of PACAP 6-38 did not significantly alter cytosolic
Ca2+ concentration of chondrogenic cells as it was also demon-
strated by others in chromaffin cells [75]. We suppose that H2O2
treatments inhibited cartilage formation partly via raising intra-
cellular Ca2+ concentration over a certain threshold, while
PACAPs, especially PACAP 6-38, by modestly lowering Ca2+
concentration, may play a balancing role in the regulation of this
cellular parameter. This might be one of the mechanisms by which
PACAPs rescued or stimulated cartilage formation in this model.
Furthermore, the elevated intracellular Ca2+ concentration
increased the activity of calcineurin following PACAP treatments
compared to controls, supporting the hypothesis that a certain
range of the elevated Ca2+ concentration has positive effects on
Ca2+-dependent signalling pathways, and sustaining the resting
intracellular Ca2+ concentration in a tolerable range during
oxidative stress by PACAPs may prevent the harmful effects of
oxidative stress on signalling pathways of chondrogenic cells.
In summary, our results demonstrate for the first time that
chondrogenic cells express molecular elements of PACAP
signalling during cartilage differentiation and PACAPs have a
chondrogenesis-promoting effect. Moreover, PACAPs rescued
cartilage formation during H2O2-induced oxidative stress, which
raises the possibility of the application of PACAPs as a
chondroprotecting/regeneration stimulating substance during
inflammatory joint diseases. Our findings suggest that PACAPs
exert their effects via complex signalling mechanisms with
considerable cross-talk and we propose that the Ca2+-calmodulin
dependent PP calcineurin is one of the downstream targets of
PACAPs in chondrogenic cells.
Supporting Information
Figure S1 Concentration-dependent effects of PACAP on
cartilage formation of HDC. PACAP 1-38 at 10 mM, PACAP
6-38 at 100 nM and 10 mM were administrated continuously from
day 1. Metachromatic cartilage areas in 6-day-old cultures were
visualized with DMMB dissolved in 3% acetic acid. Metachro-
matic (purple) structures represent cartilaginous nodules formed by
many cells and cartilage matrix rich in polyanionic GAG chains.
Original magnification was 46. Scale bar, 500 mm. Optical
density (OD625) was determined in samples containing TB
extracted with 8% HCl dissolved in absolute ethanol. Represen-
tative data of 3 independent experiments are shown.
(PDF)
Figure S2 Effect of H2O2 with or without PACAPs on
apoptotic rate of cells in 3-day-old HDC. Cellular viability
was determined by FACS analysis. Quadrants 1, 2 and 4 represent
cells containing propidium-iodide and/or Annexin V (i.e. dead
cells), whereas quadrant 3 represents unstained (i.e. living) cells of
various sizes. Representative data of 3 independent experiments.
(C, control; P1-38, PACAP 1-38; P6-38, PACAP 6-38).
(PDF)
Figure S3 Statistical analysis of RT-PCR and Western
blot results of Figs. 1, 2, 3, 5 and 6. All data are the average
of at least three different experiments. Statistical analysis was
performed by One Way ANOVA test combined with post hoc
tests. All data were normalized on GAPDH and data are expressed
as mean 6 SEM.
(PDF)
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